The measure, dubbed the PACT Act 3.0, targets drug manufacturers and pharmacy benefit managers. They have been the subject of intense debates in statehouses and Congress, as lawmakers’ attempts to make life-saving drugs more accessible and affordable collided with the interests of some of the most deep-pocketed and influential industries in the country.
Read More